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ABSTRACT
Objective: To assess the pharmacokinetics and
safety of liquid palivizumab compared with
lyophilized palivizumab.
Methods: This phase 2, randomized, double-
blind crossover study included premature
infants aged B6 months born B35 weeks
gestational age. Patients were randomized in a
1:1 ratio to receive a single 15 mg/kg
intramuscular dose of liquid (sequence A
group) or lyophilized (sequence B group)
palivizumab on Day 0. Patients crossed over to
receive the alternate formulation on Day 30.
Serum palivizumab and antidrug antibody
(ADA) levels were measured on Day 0
(predose), Day 30 (before the dose of alternate
formulation), and Day 60 (30 days after the dose
of alternate formulation). Patients were
followed for safety through Day 60 (30 days
after the dose of alternate formulation).
Results: A total of 153 infants were randomized
into the study (sequence A 75; sequence B 78).
Sequence A and sequence B trough serum
palivizumab levels were similar on Day 30 (51.7
and 49.1 lg/mL, respectively) and Day 60 (84.8
and 87.2 lg/mL, respectively). The ratio of the
geometric means using both Day 30 and Day 60
serum concentrations was 1.040 (90% CI
0.998–1.083), which was within the prespecified
bioequivalence range of 0.8–1.25. Adverse events
(AEs) were similar between the palivizumab
liquid and lyophilized groups and within each
treatment sequence. Serious AEs (SAEs) were
experienced by 3% of infants in both liquid
palivizumab and lyophilized palivizumab groups.
None of the SAEs were determined to be related to
study drug. Among the 124 infants (81% of total)
evaluated for ADA, 2 (1.6%) tested positive for
ADA at Day 60 (1 in each of sequence A and B).
Conclusion: Liquid and lyophilized formulations
of palivizumab were bioequivalent with similar
safety profiles in infants.
Trial registration: ClinicalTrials.gov #NCT00240929.
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INTRODUCTION
Respiratory syncytial virus (RSV) is a viral
pathogen that is a common cause of acute
lower respiratory infection in infants and
children worldwide [1]. By 2 years of age, most
children have been infected with RSV at least
once [2]. The risk for severe RSV is particularly
high in children who were born prematurely, or
who have congenital heart disease (CHD), or
chronic lung disease of prematurity (CLDP) [2].
In 2005, it was estimated that there were 33.8
million cases of RSV-associated acute lower
respiratory infection worldwide in
children\5 years of age [1]. Of these, 3.4
million were severe and required
hospitalization, and 66,000–199,000 cases
resulted in death [1].
Respiratory syncytial virus immune globulin
(RespiGam, MedImmune, Gaithersburg, MD,
USA) was the first RSV-specific prevention used
in high-risk infants [3]. Although this therapy
was effective, it required several hours of an
intravenous (IV) infusion [3]. Palivizumab
(MedImmune, Gaithersburg, MD, USA), an
F-protein–specific humanized monoclonal
antibody, was the first monoclonal antibody
developed to prevent an infectious disease and
represented an advance in RSV prevention.
Palivizumab was approved by the Food and
Drug Administration (FDA) in 1998 and is
indicated for the prevention of serious lower
respiratory tract disease caused by RSV in
children at high risk for RSV disease [3]. In
addition, palivizumab offers a more convenient,
intramuscular (IM), route of administration
[4]. Palivizumab was first manufactured as
a lyophilized powder [5]. Lyophilized
palivizumab is administered at a dose of
15 mg/kg IM monthly throughout the RSV
season [4]. The efficacy of lyophilized
palivizumab is well established; results from
three randomized, placebo-controlled studies
have shown that palivizumab resulted in a
45–82% reduction in RSV hospitalizations [6–
8]. However, lyophilized palivizumab requires
reconstitution with sterile water, which takes
approximately 20 min, and the drug must be
used within 6 h of reconstitution [5]. A liquid
formulation of palivizumab bypasses the need
for reconstitution and simplifies the
administration of palivizumab. This liquid
formulation was approved by the FDA in 2004
based, in part, on the results of this study [5],
and has been the only formulation distributed
in the United States since 2006. The reduced
time required for administration of liquid versus
lyophilized palivizumab has additional clinical
relevance in that it enables high-risk infants to
spend less time in a healthcare provider’s
waiting room, thereby decreasing their
exposure to other sick children visiting the
pediatrician. Single-dose pharmacokinetics (PK)
and safety profile of the liquid formulation of
palivizumab administered IV and IM were first
tested and compared with the lyophilized
formulation in 53 healthy adult volunteers. In
this parallel cohort study, liquid palivizumab
demonstrated PK and safety profiles similar to
those of lyophilized palivizumab [9].
The goal of the current study was to establish
bioequivalence and safety of the liquid
formulation in a pediatric population for
whom palivizumab is approved. This
randomized, crossover study assessed the PK,
safety, and tolerability of the liquid formulation
compared with the lyophilized formulation of
palivizumab in infants B6 months of age who
were born B35 weeks gestational age.
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METHODS
Patients
Infants aged B6 months who were born
B35 weeks gestational age were included in
the study. Infants were excluded if they were
hospitalized or receiving mechanical
ventilation at the time of study entry; had
CLDP, CHD, renal impairment, hepatic
dysfunction, chronic seizure disorder, or
immunodeficiency; had acute illness or
progressive clinical disorder; had a history of
recent difficult venous access; had an active
infection; or had ever received palivizumab.
Study approval was obtained by appropriate
institutional review board(s) (Supplementary
Appendix) before initiation. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1975, as revised in 2000. Written informed
consent was obtained from each study patient’s
parent or legal guardian before study entry or
any study procedures were performed.
Study Drug
Liquid palivizumab was provided in 3-mL vials
containing 100 mg/mL of sterile liquid product
in a volume of 1.2 mL (25 mM histidine,
1.6 mM glycine, at pH 6.0). Lyophilized
palivizumab was provided in 5-mL vials
containing 100 mg of sterile lyophilized
product (25 mM histidine, 1.6 mM glycine,
and 3% w/v mannitol at pH 6.0, before
lyophilization) that yielded palivizumab at a
concentration of 100 mg/mL after
reconstitution with 1 mL of sterile water for
injection. Study medications were administered
at a dose of 15 mg/kg IM.
Study Design
This phase 2, randomized, double-blind,
2-period crossover study (NCT00240929) was
conducted at 21 sites in the United States.
Patients were randomized from November 2002
through February 2003 in a 1:1 ratio to either
the sequence A group or the sequence B group
(Fig. 1). Study medication was supplied to the
pharmacy as open-labeled lyophilized or liquid
palivizumab. The pharmacist prepared the
study medication with the appropriate
formulation, and the medication was
dispensed from the pharmacy in identical
syringes. The investigators, study nurses, and
patient’s parents were blinded to the study
medication. Patients received a single 15 mg/
kg IM dose of liquid (sequence A) or lyophilized
(sequence B) palivizumab on Day 0. Patients
crossed over to receive the alternate
formulation on Day 30. The design and
endpoints of the trial were finalized following
regulatory input. After study completion (i.e.,
after patients had received 2 doses of study
drug), investigators were free to give patients
additional doses of commercially available
lyophilized palivizumab for the remainder of
the RSV season. Liquid palivizumab was not
commercially available at the time of the study
and was used only in the experimental setting.










Sequence A   N=75
Liquid palivizumab, 15 mg/kg
Lyophilized palivizumab, 15 mg/kg
Sequence B    N=75
Safety and PK follow-up
Visit 2 31
Fig. 1 Study design. PK pharmacokinetics
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Pharmacokinetics
Bioequivalence was assessed by comparing the
relative bioavailability of the two palivizumab
formulations. Because the indicated patient
population for palivizumab consists of preterm
infants from whom only limited numbers of
blood samples and total blood volume could be
collected, the standard bioequivalence
parameters of maximum concentration (Cmax)
and area under the curve (AUC), which require
a full PK profile, could not be used to establish
bioequivalence. Serum samples for determining
palivizumab concentrations were collected at
baseline, on study Day 30 (before the dose of
alternate formulation), and study Day 60
(30 days after the dose of alternate
formulation). Serum samples were analyzed at
a central laboratory (PPD Development,
Richmond, VA, USA) to determine
palivizumab concentration using a validated
enzyme-linked immunosorbent assay (ELISA)
[10]. The ELISA used for measuring serum
palivizumab concentration was developed by
MedImmune and provides linear results in the
range 10–750 lg/mL. Patient samples with
concentrations below the lower limit of
quantitation (LLOQ) of the assay of 10 lg/mL
were reported as \LOQ. Results were analyzed
using Softmax Pro 2.2.1 software (Molecular
Devices Corporation, Sunnyvale, CA, USA).
Safety
Adverse events (AEs) were monitored for
30 days after each study drug injection. AEs
and serious AEs (SAEs) were graded by severity
(level 1–4) and relationship to study drug (none,
remote, possible, probable, or definite) by the
study investigator. AEs were considered related
to the study medication (as determined by the
blinded site investigator) if they were reported
as possibly, probably, or definitely related. SAEs
included those that resulted in death; were life-
threatening; or resulted in inpatient
hospitalization or prolongation of existing
hospitalization [11].
Antidrug Antibodies
Serum samples for determining antidrug
antibodies (ADA) to palivizumab from patients
who had previously consented to additional
testing were collected at baseline and on study
Days 30 and 60. ADA assays were performed
with the qualified assay described in previous
studies [10]. Patient serum samples and negative
and positive controls were diluted 1:10 before
performing the assay. Solutions were incubated
for 1 h, and anti-palivizumab immunoglobulin
was detected with horseradish peroxidase-
conjugated palivizumab. A titer [1:10 was
considered positive for ADA. Results were
analyzed using Softmax Pro 3.2.1 software
(Molecular Device Corporation).
Statistical Analyses
The PK analysis included all patients receiving
two full doses of study drug, without major
protocol violations, and for whom the study
visits occurred within the specified visit
windows. All patients who received study drug
were included in the safety summaries.
An enrollment goal of 60 per sequence group
was initially calculated based on estimates of
between-patient and within-patient variability
obtained from previous studies, and was
calculated to yield an 80% chance that the 90%
confidence interval (CI) of the within-patient
206 Infect Dis Ther (2014) 3:203–214
standard deviations (SD) of the log trough
concentration would be between 0.80 and 1.25.
The sample size was increased to 75 because of
potential difficulties in obtaining adequate
blood samples from infants, and to allow for
withdrawals and dropouts in the study.
An analysis of variance (ANOVA) was
performed on log-transformed 30-day
postdose serum concentrations, which
included both Day 30 and Day 60 trough
serum concentrations due to the crossover
design. The model accounted for all sources of
variation that could be reasonably assumed to
have an effect on the serum concentration,
namely, sequence, patient, formulation, and
period. The geometric means of the trough
concentration (Ctrough) for each formulation,
the ratio of the geometric means (with the
lyophilized formulation as the reference
group) and the associated 90% CI were
estimated. If the 90% CI for the ratio of the
geometric means of the Ctrough was within
0.8–1.25 of the statistical interval, the two
formulations would be considered
bioequivalent. The CI was to be constructed
only if a significant sequence effect was not
demonstrated. If a significant sequence effect
was demonstrated, a 90% CI using only the
Day 30 data was to be constructed.
This additional CI is reported here for
convenience.
The incidence of AEs was summarized
separately for liquid and lyophilized
palivizumab during each of the 3 study
periods: study Days 0–30 (i.e., from after the
first injection through 30 days or up to the date
of the second injection), study Days 30–60 (i.e.,
from after the second injection through
30 days), and study Days 0–60 (i.e., through
the respective 30-day follow-up periods for
patients receiving study drug at study Day 0,
study Day 30, or both).
RESULTS
Patients
A total of 153 patients were randomized into
the study (75 to sequence A, 78 to sequence B),
and 152 completed the study through 30 days
after the second injection of the study drug.
One infant in the sequence B group did not
complete the study as their parents withdrew
consent after the first study drug injection.
Generally, demographic and baseline
characteristics were similar between the
sequence A and sequence B groups (Table 1).
Pharmacokinetics
The trough serum palivizumab levels on study
Days 30 and 60 were similar in both sequence
groups. The geometric mean trough serum
palivizumab levels obtained on study Day 30
were 51.7 lg/mL in the sequence A group
(30 days after receipt of liquid palivizumab)
and 49.1 lg/mL in the sequence B group
(30 days after receipt of lyophilized
palivizumab), reflecting similarity in trough
concentrations following liquid and
lyophilized formulations, respectively
(Table 2). The arithmetic mean (SD) levels
obtained on study Day 30 were 54.8 (20.1) lg/
mL in the sequence A group and 51.6 (17.5) lg/
mL in the sequence B group. On study Day 60,
the geometric mean trough serum palivizumab
levels were 84.8 lg/mL with sequence A and
87.2 lg/mL with sequence B, and the arithmetic
mean (SD) levels were 88.6 (27.0) lg/mL with
sequence A and 90.9 (26.7) lg/mL with
sequence B. The trough levels increased for all
patients in sequence A, and in all but three
patients in sequence B, from study Day 30 to
study Day 60; mean (SD) trough levels are
shown in Fig. 2. Using an ANOVA model, the
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ratio of the geometric means of the Ctrough for
each formulation was 1.040 and its associated
90% CI was 0.998–1.083, which was within the
bioequivalence limits of 0.8–1.25 (Table 2). The
results of the ANOVA detected a significant
period effect, as expected, due to accumulation
of concentrations after the second dose;
however, the ANOVA did not detect a
statistically significant formulation or
sequence effect, indicating no evidence of a
differential carryover effect between the 2
sequences. Analyzed as a parallel study
(Table 2), the ratio of the geometric means of
the Day 30 Ctrough was 1.051 (90% CI
0.963–1.148), which was also within the
bioequivalence limits of 0.8–1.25.
Safety
Overall, 50.0% (76/152) of infants receiving
liquid palivizumab and 49.0% (75/153)
receiving lyophilized palivizumab experienced
C1 AE from study Days 0–60. The AEs were
generally similar between the two groups, and
the most common AEs overall were typical for
the population of infants B6 months of age
with a history of prematurity (Table 3). The
proportion of infants with C1 AE reported
during each of the Day 0–30 and 30–60 study
periods was similar between the liquid and
lyophilized palivizumab groups (Table 4) and
within each treatment sequence. The number
of infants with C1 AE was slightly higher after
the first injection than after the second
injection for both sequence A and sequence
B. Most AEs were level 1 or 2 in severity. Only
4 AEs in the liquid palivizumab group (fever,
injection site reaction; n = 2 each) and 2 AEs
in the lyophilized palivizumab group
(injection site reaction, pneumonia) were
considered to be related to study
medication. No deaths occurred during the
study. From study Days 0–60, the number of
SAEs was the same for each group (n = 5),
representing 5 (3.3%) and 4 (2.6%) infants in
the liquid and lyophilized palivizumab
groups, respectively (Table 5). Generally,
SAEs were similar between the liquid and
lyophilized palivizumab groups and were also
similar after each injection in both the
sequence A and B groups (Table 5). None of






Male 42 (56.0) 39 (50.0)
Female 33 (44.0) 39 (50.0)
Race, n (%)
White/non-Hispanic 36 (48.0) 39 (50.0)
Black 26 (34.7) 18 (23.1)
Hispanic 9 (12.0) 14 (17.9)
Asian 2 (2.7) 2 (2.6)
Other 2 (2.7) 5 (6.4)
Age at study entry, months
Mean (SE) 1.6 (0.2) 1.4 (0.2)
Range 0.1–5.4 0.1–5.3
Weight at study entry, kg
Mean (SE) 3.4 (0.2) 3.4 (0.2)
Range 1.7–8.1 1.7–8.4
Gestational age, weeks
Mean (SE) 33.5 (0.2) 33.3 (0.2)
Range 29.0–35.0 28.0–35.0
Birth weight, kg
Mean (SE) 2.0 (0.0) 2.1 (0.0)
Range 1.0–3.1 1.2–3.2
SE standard error
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the SAEs were considered to be related to
palivizumab.
Antidrug Antibodies
ADAs were assessed in 81.3% (61/75) of infants
in sequence A and 83.3% (65/78) of infants in
sequence B. Of these, 1.6% (2/126) tested
positive for ADA (defined as a titer C1:10).
One infant in sequence A (1/61; 1.6%) had a
titer of 1:40 at study Day 60 and another infant
in sequence B (1/65; 1.5%) had a titer of 1:10 at
study Day 60.
DISCUSSION
Similarity in PK and safety of liquid and
lyophilized formulations after 3 mg/kg
administered IM and 15 mg/kg administered
IV was first assessed in healthy adult volunteers
in a double-blinded fashion [9]. Liquid and
lyophilized palivizumab had similar safety
profiles, with no serious AEs reported [9]. Both
formulations of palivizumab also exhibited
similar PK profiles, with mean [standard error
(SE)] Cmax of 32.6 (2.35) lg/mL and 29.6
(2.84) lg/mL, and mean (SE) AUC of 890
Table 2 Bioequivalence
Geometric mean palivizumab 15 mg/kg IM Ratio of geometric
meana
90% CI
Liquid (n5 73) Lyophilized (n5 76)
Primary analysis 67.1 64.5 1.040 (0.998, 1.083)
Sensitivity analysis
(using only Day 30 data)
51.7 49.1 1.051 (0.963, 1.148)
CI conﬁdence interval, Ctrough trough concentration, IM intramuscular























































Day 30 Day 60
Fig. 2 Mean (SD) trough serum palivizumab concentrations on Day 30 and Day 60 (30 days postdose)
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(111.5) lg 9 day/mL and 844 (119.9) lg 9 day/
mL in the 3 mg/kg IM liquid and lyophilized
groups, respectively, and mean (SE) Cmax of
502.5 (35.89) lg/mL and 585 (32.40) lg/mL,
and mean (SE) AUC of 6,673 (749.2) lg 9 day/
mL and 6,310 (414.2) lg 9 day/mL in the
15 mg/kg IV liquid and lyophilized groups,
respectively [9].
Based on the similarity in palivizumab PK
between the two formulations in the
exploratory study in adults, our current study
was designed to evaluate bioequivalence with
respect to serum concentrations and to assess
similarity in safety between liquid and
lyophilized formulations in children at high
risk for RSV disease. A crossover design was used
since this allows for the assessment of
bioequivalence while minimizing the impact
of subject-to-subject variability on the results of
the analysis. Given that palivizumab is
administered monthly in infants, serum
trough concentrations were used to assess
similarity in palivizumab exposures between
lyophilized and liquid formulations in a
crossover fashion.
An analysis of palivizumab PK across 22
studies (including data from the current study)
[12] showed that body weight impacts
palivizumab exposure, and gestational age
only has a minimal effect on palivizumab
concentrations. Across a range of gestational
and postnatal ages, palivizumab serum
concentrations were similar, suggesting the
appropriateness of body weight dosing [12].
Moreover, palivizumab 15 mg/kg demonstrated
comparable therapeutic concentrations in
patients with different demographic
characteristics [12].
Findings from this study of infants
aged B6 months with a history of prematurity
of B35 weeks gestation showed that liquid and
lyophilized palivizumab formulations exhibit
comparable PK and similar safety profiles.
Similar trough palivizumab levels were
observed between the two sequence groups
and the 90% CIs for the ratios of least squares
geometric means of trough levels for the two
formulations were within the 90% confidence
limits for bioequivalence.
The half-life of palivizumab is approximately
20 days; palivizumab accumulation is expected
upon redosing on Day 30 based on the
frequency of dosing compared with the half-
life. The trough serum palivizumab levels in the
present study were generally consistent with the
Table 3 Adverse events in C5 patients in either the liquid
or lyophilized palivizumab group overall (study Days
0–60)






Total events 113 110
Infants with C1 event 76 (50.0) 75 (49.0)
URI 14 (9.2) 18 (11.8)
Fever 11 (7.2) 8 (5.2)
Rhinitis 9 (5.9) 11 (7.2)
Gastrointestinal disorder 9 (5.9) 8 (5.2)
Otitis media 8 (5.3) 3 (2.0)
Rash 7 (4.6) 7 (4.6)
Nervousness 6 (3.9) 0 (0.0)
Diarrhea 5 (3.3) 3 (2.0)
Hernia 4 (2.6) 4 (2.6)
Oral moniliasis 3 (2.0) 5 (3.3)
Injection site reaction, other 3 (2.0) 2 (1.3)
Conjunctivitis 2 (1.3) 5 (3.3)
Vomiting 2 (1.3) 4 (2.6)
Pain 2 (1.3) 3 (2.0)
RSV 2 (1.3) 3 (2.0)
AE adverse event, RSV respiratory syncytial virus, URI
upper respiratory tract infection
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levels previously reported from the randomized,
double-blind, placebo-controlled efficacy study
in infants B35 weeks gestation and\6 months
of age or B2 years of age with CLDP, in which
mean trough serum levels through 30 days after
the first and second doses were 37 and 57 lg/
mL, respectively, after 15 mg/kg of lyophilized
palivizumab [8]. Serum levels from a phase 2,
randomized, double-blind study of liquid
palivizumab in premature infants with and
without CLDP showed a mean trough serum
palivizumab level of 87.4 lg/mL on Day 60 [13].
It is difficult to compare absolute levels between
studies, given the subtle differences in assays or
study conduct, which could lead to different
results. However, all studies have shown higher
values at Day 60 relative to Day 30 due to
accumulation of palivizumab with repeated
dosing.
Liquid palivizumab has been used in the
United States since its FDA approval in 2004
and has demonstrated a similar safety profile to
lyophilized palivizumab in the postmarketing
setting. In the current study, a similar incidence
Table 4 Adverse events in C5 patients in either the liquid or lyophilized palivizumab group (Study Days 0–30 and 30–60)













Total events 63 62 50 48
Infants with C1 event 40 (53.3) 41 (52.6) 36 (46.8) 34 (45.3)
URI 7 (9.3) 9 (11.5) 7 (9.1) 9 (12.0)
Fever 6 (8.0) 4 (5.1) 5 (6.5) 4 (5.3)
Rhinitis 4 (5.3) 6 (7.7) 5 (6.5) 5 (6.7)
Gastrointestinal disorder 5 (6.7) 5 (6.4) 4 (5.2) 3 (4.0)
Otitis media 3 (4.0) 2 (2.6) 5 (6.5) 1 (1.3)
Rash 4 (5.3) 4 (5.1) 3 (3.9) 3 (4.0)
Nervousness 4 (5.3) 0 (0.0) 2 (2.6) 0 (0.0)
Diarrhea 3 (4.0) 2 (2.6) 2 (2.6) 1 (1.3)
Hernia 2 (2.7) 3 (3.8) 2 (2.6) 1 (1.3)
Oral moniliasis 3 (4.0) 4 (5.1) 0 (0.0) 1 (1.3)
Injection site reaction, other 0 (0.0) 0 (0.0) 3 (3.9) 2 (2.7)
Conjunctivitis 2 (2.7) 2 (2.6) 0 (0.0) 3 (4.0)
Vomiting 2 (2.7) 2 (2.6) 0 (0.0) 2 (2.7)
Pain 1 (1.3) 2 (2.6) 1 (1.3) 1 (1.3)
RSV 1 (1.3) 2 (2.6) 1 (1.3) 1 (1.3)
AE adverse event, RSV respiratory syncytial virus, URI upper respiratory tract infection
a Sequence A
b Sequence B
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of AEs was observed regardless of palivizumab
formulation or the sequence of palivizumab
administration. The incidence of SAEs was also
similar between the liquid and lyophilized
palivizumab groups. The AEs considered to be
related to the study medications in the present
study were consistent with those reported in a
larger study with lyophilized palivizumab,
including fever (2.8%), nervousness (2.5%),
and injection site reaction (2.3%) [8].
Additionally, the AEs reported in the present
study were generally consistent with those
reported in a large (n = 3,306) study of infants
who received liquid palivizumab [14]. The most
commonly reported AEs in that study were
upper respiratory tract infection (30.1%),
pyrexia (16.9%), and rhinitis (13.5%) [14].
Overall, the reported AEs and SAEs were
generally as expected for the studied
population of infants B6 months of age with a
history of prematurity.
The crossover study design, a strength of this
study, allowed for the evaluation of the safety of
the sequential exposure of one palivizumab
formulation to another. One of the limitations
of the study is that there was no washout
period. A drug washout period of approximately
3 months would have potentially placed these
infants at risk during the RSV season. This
crossover design, with the alternative
formulation administered at the next
scheduled monthly dosing period, was also felt
to mimic a potential clinical situation where
infants receiving lyophilized palivizumab could
be switched to the liquid formulation within a
single RSV season. The ANOVA demonstrated
no significant differential carryover effect.
Moreover, the geometric mean ratio and
Table 5 Serious adverse events



















Total events 3 3 2 2 5 5
Infants with C1 event 3 (4.0) 2 (2.6) 2 (2.6) 2 (2.7) 5 (3.3) 4 (2.6)
RSV 1 (1.3) 1 (1.3) 0 0 1 (0.7) 1 (0.7)
Fever 1 (1.3) 0 0 0 1 (0.7) 0
Gastroenteritis 0 0 1 (1.3) 0 1 (0.7) 0
Gastrointestinal disorder 0 0 1 (1.3) 0 1 (0.7) 0
Pneumonia 1 (1.3) 0 0 0 1 (0.7) 0
Apnea 0 1 (1.3) 0 0 0 1 (0.7)
Dehydration 0 0 0 1 (1.3) 0 1 (0.7)
Urinary tract infection 0 1 (1.3) 0 0 0 1 (0.7)
Vomiting 0 0 0 1 (1.3) 0 1 (0.7)
RSV respiratory syncytial virus, SAE serious adverse event
a Sequence A
b Sequence B
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associated 90% CI constructed after a single
dose using Day 30 Ctrough data alone were
within the bioequivalence limits, supporting
the bioequivalence conclusion in the absence of
a washout period in this study.
In conclusion, findings from this study show
comparable PK profiles of the liquid and
lyophilized formulations of palivizumab in
infants, supporting the bioequivalence of the
two formulations. The safety profiles were also
similar between the liquid and lyophilized
formulations of palivizumab in the studied
pediatric population.
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